Lexaria gets AUD$3.7M Australian R&D tax credit

Lexaria Bioscience Corp. (LEXX) disclosed that its wholly owned Australian subsidiary, Lexaria (AU) Pty Ltd, received an Australian R & D Tax Incentive Credit of AUD$3,666,611.98 on August 28, 2026.

Rhea-AI Filing Summary

Lexaria Bioscience Corp. (LEXX) disclosed that its wholly owned Australian subsidiary, Lexaria (AU) Pty Ltd, received an Australian R & D Tax Incentive Credit of AUD$3,666,611.98 on August 28, 2026. The credit relates to research and development costs for its Australian clinical study GLP-1-H24-4.

The funds have been deposited into the subsidiary’s Australian bank account and are intended to be used to pursue additional research and development opportunities in Australia. Lexaria (AU) holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products in Australia.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Australian R & D Tax Incentive Credit: AUD$3,666,611.98 Date of receipt of tax credit: August 28, 2026 Par value of Common Stock: $0.001 per share +1 more

4 metrics

Australian R & D Tax Incentive Credit AUD$3,666,611.98 Amount received by Lexaria (AU) Pty Ltd related to clinical study GLP-1-H24-4

Date of receipt of tax credit August 28, 2026 Date Lexaria (AU) Pty Ltd received the Australian R & D Tax Incentive Credit

Par value of Common Stock $0.001 per share Par value of Lexaria Bioscience Corp. common stock listed on The Nasdaq Capital Market

Registrant telephone number (250) 765-6424 Telephone number for Lexaria Bioscience Corp.’s principal executive offices

Key Terms

Australian R & D Tax Incentive Credit, DehydraTECH technology, GLP-1/GIP, GLP-1-H24-4

4 terms

Australian R & D Tax Incentive Credit financial

"received a tax credit in the amount of AUD$3,666,611.98 from the Australian Tax Office"

DehydraTECH technology technical

"holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP"

GLP-1/GIP medical

"use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products"

GLP-1-H24-4 medical

"research and development costs associated with its Australian clinical study GLP-1-H24-4"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What tax credit did Lexaria Bioscience Corp. (LEXX) receive in Australia?

Lexaria’s Australian subsidiary received an Australian R & D Tax Incentive Credit of AUD$3,666,611.98 related to research and development costs for its clinical study GLP-1-H24-4.

When did LEXX receive the Australian R & D Tax Incentive Credit?

Lexaria (AU) Pty Ltd received the Australian R & D Tax Incentive Credit on August 28, 2026, from the Australian Tax Office in connection with research and development costs for study GLP-1-H24-4.

How much was the Australian R & D Tax Incentive Credit received by LEXX?

Lexaria’s Australian subsidiary received a tax credit of AUD$3,666,611.98 under the Australian R & D Tax Incentive program, tied to R&D expenses for its clinical study GLP-1-H24-4.

How will Lexaria Bioscience Corp. (LEXX) use the Australian tax credit funds?

The AUD$3,666,611.98 tax credit has been deposited into Lexaria (AU) Pty Ltd’s Australian bank account and is intended for pursuing additional research and development opportunities in Australia.

What exclusive rights does Lexaria (AU) Pty Ltd hold for LEXX in Australia?

Lexaria (AU) Pty Ltd holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products in the territory of Australia.

Which Lexaria study is linked to the Australian R & D Tax Incentive Credit for LEXX?

The credit is linked to research and development costs associated with Lexaria’s Australian clinical study GLP-1-H24-4, for which Lexaria (AU) Pty Ltd received the R & D Tax Incentive Credit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 09:16 AM EDT Accepted by SEC EDGAR 09/01/2026 - 09:16 AM EDT Learn about SEC filing dates

0001348362false00013483622026-08-282026-08-28iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 28, 2026 

LEXARIA BIOSCIENCE CORP.

(Exact name of registrant as specified in its charter)

Nevada		000-39874								20-2000871
(State or other jurisdiction of incorporation)		(Commission File Number)								(IRS Employer Identification No.)

100 – 740 McCurdy Road, Kelowna, BC Canada						V1X 2P7
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code (250) 765-6424 

______________________________________________  

(Former name or former address, if changed since last report.) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		LEXX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events 

Receipt of Australian R & D Tax Incentive Credit

On August 28, 2026, Lexaria (AU) Pty Ltd, the wholly-owned subsidiary of Lexaria Bioscience Corp. which holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products in the territory of Australia, received a tax credit in the amount of AUD$3,666,611.98 (USD$2.6M), from the Australian Tax Office (the “Credit”) in connection with the research and development costs associated with its Australian clinical study GLP-1-H24-4.

The Credit has been deposited into the Australian bank account of Lexaria (AU) Pty Ltd for the intended purpose of pursuing additional research and development opportunities in Australia.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LEXARIA BIOSCIENCE CORP.
Date: September 1, 2026	By:	/s/ Richard Christopher
		Richard Christopher
		CEO, Principal Executive Officer

3

Filing Exhibits & Attachments

5 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 14.3 KB
• EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE 898 B
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 9.0 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 2.0 KB